Needham Maintains Buy on AtriCure, Lowers Price Target to $34
Needham Maintains Buy on AtriCure, Lowers Price Target to $34
Needham維持對atricure的買入評級，將目標股價下調至34美元。
Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $40 to $34.
Needham的分析師Mike Matson維持對AtriCure（納斯達克代碼：ATRC）的買入評級並將目標價從40美元降至34美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。